The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V ...

GSK’227 is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. The Food and Drug Administration (FDA ...

“This is a ‘copy and paste’-type process, which overwrites existing genes to increase diversity,” said Ke-Yi Lin, Principal Scientist and CMC ... as an antibody–drug conjugate for ...

In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.

The Japanese unit is tapping Zurich-based Araris Biotech to develop new antibody-drug conjugates, which nets Araris an upfront fee and up to $780 million in potential milestone payments.

The pharmaceutical giant will pay the smaller firm up to $350 million to use software models to design new small molecules as well as antibody-drug conjugates, or ADCs. ADCs are new territory ...

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers First Investigational New Drug (IND) submission ...

Co., Ltd. (“MediLink”) to use MediLink’s TMALIN ® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.

Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.